Greenwich Biosciences is at the forefront of cannabinoid science, leveraging nearly two decades of pioneering investment and research by our parent company GW Pharmaceuticals plc.

Our legacy is rooted in unlocking the potential of cannabinoid prescription medicines to address serious conditions that currently have limited or no treatment options.


Our enduring commitment to scientific rigor and exacting pharmaceutical manufacturing standards enables us to bring forward plant-derived cannabinoid prescription medicines for patients.

Greenwich Biosciences is the first and only company to pursue and receive FDA approval for a plant-derived cannabinoid therapy that addresses difficult to treat conditions with significant unmet needs.